Aisling Capital Management’s Bicara Therapeutics BCAX Stock Holding History

Aisling Capital Management’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.3M	Hold	568,919	–	–	2.38%	4
2025 Q4	$9.57M	Hold	568,919	–	–	2%	4
2025 Q3	$8.98M	Hold	568,919	–	–	1.97%	6
2025 Q2	$5.29M	Hold	568,919	–	–	1.47%	5
2025 Q1	$7.41M	Hold	568,919	–	–	2.57%	4
2024 Q4	$9.91M	Hold	568,919	–	–	3.52%	6
2024 Q3	$14.5M	Buy	+568,919	New	+$14.5M	5.55%	4

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Aisling Capital Management's BCAX Position: Q1 2026 in Review

Aisling Capital Management held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 568,919 shares worth $11.3M. The position accounts for 2.38% of the portfolio, ranked #4.

Aisling Capital Management first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.5M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

Aisling Capital Management held 568,919 shares of Bicara Therapeutics worth $11.3M as of Q1 2026.
Aisling Capital Management left its Bicara Therapeutics share count unchanged in Q1 2026.
Bicara Therapeutics made up 2.38% of Aisling Capital Management's portfolio in Q1 2026, its #4 holding.
Aisling Capital Management first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
Aisling Capital Management's Bicara Therapeutics position peaked at $14.5M in Q3 2024.
146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Aisling Capital Management's 13F filing for Q1 2026, filed 5 May 2026.